FDA authorized MSKCC’s tumor profiling tests

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA authorized Memorial Sloan Kettering Cancer Center’s Integrated Mutation Profiling of Actionable Cancer Targets tumor profiling test, an in vitro diagnostic test that can identify a higher number of genetic mutations that may be found in various cancers than any test previously reviewed by the agency.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login